LAVA Therapeutics Agrees to Acquisition by XOMA

The latest announcement is out from LAVA Therapeutics ( (LVTX) ).

On August 3, 2025, LAVA Therapeutics entered into a share purchase agreement with XOMA Royalty Corporation, whereby XOMA will acquire all of LAVA’s outstanding shares through a tender offer. The acquisition, valued between $1.16 and $1.24 per share, includes a contingent value right for potential future payments. LAVA’s Board has endorsed the transaction, considering it beneficial for shareholders and stakeholders. Following the acquisition, LAVA will undergo a corporate reorganization, resulting in it no longer being publicly traded, and its shares will be delisted from Nasdaq. The transaction is expected to close in the fourth quarter of 2025, and LAVA plans to discontinue its Phase 1 clinical trial of LAVA-1266.

The most recent analyst rating on (LVTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.

Spark’s Take on LVTX Stock

According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.

The stock score reflects significant financial challenges, offset by positive technical indicators and corporate events. The financial performance is the most significant risk, while shareholder confidence and technical strength provide some optimism.

To see Spark’s full report on LVTX stock, click here.

More about LAVA Therapeutics

LAVA Therapeutics N.V. is a biopharmaceutical company specializing in the development of clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform. The company focuses on treatments for hematologic cancers and solid tumors, with partnerships including Johnson & Johnson and Pfizer.

Average Trading Volume: 39,322

Technical Sentiment Signal: Hold

Current Market Cap: $37.35M

Find detailed analytics on LVTX stock on TipRanks’ Stock Analysis page.